These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8790484)

  • 1. Assessing value for money in medical screening.
    Cairns JA; Shackley P
    J Med Screen; 1994 Jan; 1(1):39-44. PubMed ID: 8790484
    [No Abstract]   [Full Text] [Related]  

  • 2. [Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
    Kristoffersson U; Nørgaard-Pedersen B
    Lakartidningen; 1995 Mar; 92(12):1205-6, 1211-2. PubMed ID: 7535873
    [No Abstract]   [Full Text] [Related]  

  • 3. Population screening: report of a workshop.
    Scriver CR
    Prog Clin Biol Res; 1985; 163B():89-152. PubMed ID: 2580316
    [No Abstract]   [Full Text] [Related]  

  • 4. How far can prenatal screening go in preventing birth defects?
    Savitz DA
    J Pediatr; 2008 Jan; 152(1):3-4. PubMed ID: 18154886
    [No Abstract]   [Full Text] [Related]  

  • 5. Prenatal screening for genetic disorders: Suggested guidelines for the Indian Scenario.
    Phadke SR; Puri RD; Ranganath P
    Indian J Med Res; 2017 Dec; 146(6):689-699. PubMed ID: 29664026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA; Watson SE; Washington AE
    Obstet Gynecol; 1994 Dec; 84(6):903-12. PubMed ID: 7970468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring the benefits of screening for open neural tube defects.
    Henderson JB
    J Epidemiol Community Health; 1982 Sep; 36(3):214-9. PubMed ID: 6815296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the benefits of antenatal screening: an alternative approach.
    Shackley P; Cairns J
    Health Policy; 1996 May; 36(2):103-15. PubMed ID: 10158764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of antenatal screening for cystic fibrosis. Couple screening should be preferred for medical reasons.
    Morris J
    BMJ; 1996 Apr; 312(7035):908-9; author reply 910. PubMed ID: 8611894
    [No Abstract]   [Full Text] [Related]  

  • 10. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
    Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
    Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for cystic fibrosis.
    Haddow JE; Palomaki GE; Bradley LA; Doherty RA
    JAMA; 1998 Apr; 279(14):1068; author reply 1069. PubMed ID: 9546561
    [No Abstract]   [Full Text] [Related]  

  • 12. Testing for fetal abnormality in routine antenatal care.
    Green J; Statham H
    Midwifery; 1993 Sep; 9(3):124-35. PubMed ID: 8412833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Existence and quality of written antenatal screening policies in the United Kingdom: postal survey.
    Lane B; Challen K; Harris HJ; Harris R
    BMJ; 2001 Jan; 322(7277):22-3. PubMed ID: 11141145
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost effectiveness of antenatal screening for cystic fibrosis. Authors should have used marginal analysis.
    Torgerson DJ
    BMJ; 1996 Apr; 312(7035):909; author reply 910. PubMed ID: 8611895
    [No Abstract]   [Full Text] [Related]  

  • 15. Maternal serum screening for neural tube defects and Down's syndrome.
    Med J Aust; 1991 Aug; 155(4):279-80. PubMed ID: 1831530
    [No Abstract]   [Full Text] [Related]  

  • 16. A cost-benefit analysis of prenatal detection of Down syndrome and neural tube defects in older mothers.
    Sadovnick AD; Baird PA
    Am J Med Genet; 1981; 10(4):367-78. PubMed ID: 6460445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Orientation on genetic screening for cystic fibrosis].
    Brandt NJ; Schwartz M; Skovby F
    Ugeskr Laeger; 1991 May; 153(19):1365-8. PubMed ID: 2042248
    [No Abstract]   [Full Text] [Related]  

  • 19. Choice of serum markers in antenatal screening for Down's syndrome.
    Wald NJ; Watt HC
    J Med Screen; 1994 Apr; 1(2):117-20. PubMed ID: 8790499
    [No Abstract]   [Full Text] [Related]  

  • 20. Maternal age-specific costs of detecting Down syndrome and neural tube defects.
    Sadovnick AD; Baird PA
    Can J Public Health; 1982; 73(4):248-50. PubMed ID: 6215977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.